Stock DNA
Pharmaceuticals & Biotechnology
CNY 5,367 Million (Mid Cap)
37.00
NA
0.00%
-0.12
11.14%
4.62
Revenue and Profits:
Net Sales:
360 Million
(Quarterly Results - Jun 2025)
Net Profit:
102 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
21.79%
0%
21.79%
6 Months
8.61%
0%
8.61%
1 Year
75.2%
0%
75.2%
2 Years
3.85%
0%
3.85%
3 Years
-12.1%
0%
-12.1%
4 Years
12.44%
0%
12.44%
5 Years
0%
0%
0.0%
Beijing Sun-Novo Pharmaceutical Research Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
22.98%
EBIT Growth (5y)
1.83%
EBIT to Interest (avg)
18.77
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.08
Sales to Capital Employed (avg)
0.65
Tax Ratio
Tax Ratio is Negative%
Dividend Payout Ratio
10.29%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
25.31%
ROE (avg)
16.49%
Valuation key factors
Factor
Value
P/E Ratio
37
Industry P/E
Price to Book Value
5.24
EV to EBIT
37.75
EV to EBITDA
25.67
EV to Capital Employed
5.80
EV to Sales
5.19
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
15.36%
ROE (Latest)
14.05%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bearish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY
Jun'25
Jun'24
Change(%)
Net Sales
359.80
310.30
15.95%
Operating Profit (PBDIT) excl Other Income
135.80
100.10
35.66%
Interest
4.60
4.20
9.52%
Exceptional Items
0.00
0.00
Consolidate Net Profit
101.90
72.60
40.36%
Operating Profit Margin (Excl OI)
327.00%
268.80%
5.82%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2025 is 15.95% vs 35.92% in Jun 2024
Consolidated Net Profit
YoY Growth in quarter ended Jun 2025 is 40.36% vs 1.68% in Jun 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
1,076.50
930.90
15.64%
Operating Profit (PBDIT) excl Other Income
241.20
254.80
-5.34%
Interest
16.20
12.20
32.79%
Exceptional Items
0.00
0.00
Consolidate Net Profit
169.00
182.90
-7.60%
Operating Profit Margin (Excl OI)
160.50%
205.00%
-4.45%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 15.64% vs 37.81% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -7.60% vs 15.25% in Dec 2023
About Beijing Sun-Novo Pharmaceutical Research Co., Ltd. 
Beijing Sun-Novo Pharmaceutical Research Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






